Mineralys Therapeutics (MLYS)

• Market cap: $637M
• 1 day: 6.14%
• 5 days: 2.89%
• 1 month: 0.79%
• 3 months: 9.40%
• 6 months: 1.35%
• Year to date: 47.47%
• 1 year: 56.86%
• 5 years: -30.59%
• 10 years: -30.59%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Employees: 28

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

171% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 7

65% more call options, than puts

Call options by funds: $109K | Put options by funds: $66K

46% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 24

17% more funds holding in top 10

Funds holding in top 10: 6 [Q2] → 7 (+1) [Q3]

13% more funds holding

Funds holding: 94 [Q2] → 106 (+12) [Q3]

2% more capital invested

Capital invested by funds: $528M [Q2] → $540M (+$11.7M) [Q3]

1.7% less ownership

Funds ownership: 90.95% [Q2] → 89.25% (-1.7%) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $30 134% upside
• Avg. target: $30 134% upside
• High target: $30 134% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Matthew Caufield 24% 1-year accuracy 12 / 50 met price target

134% upside $30

Buy Reiterated

12 Nov 2024